Education
About Us
Working with TipRanks
Follow Us
Picard Medical, Inc. (PMI)
XASE:PMI
PMI Stock Chart & Stats
$1.82
--
Market closed
$1.82
--
Day’s Range― - ―
52-Week Range$1.01 - $13.68
Previous CloseN/A
VolumeN/A
Average Volume (3M)2.38M
Market Cap
N/A
Enterprise Value$1.53B
Total Cash (Recent Filing)$2.81M
Total Debt (Recent Filing)$752.00K
Price to Earnings (P/E)―
Beta-0.88
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding73,701,180
10 Day Avg. Volume2,124,305
30 Day Avg. Volume2,378,935
Financial Highlights & Ratios
PEG Ratio-0.49
Price to Book (P/B)-13.93
Price to Sales (P/S)75.32
P/FCF Ratio-27.85
Enterprise Value/Market Cap10.00T>
Enterprise Value/Revenue319.80
Enterprise Value/Gross Profit-3.19K
Enterprise Value/Ebitda-63.07
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Regulatory Approvals & Clinical LeadershipSynCardia’s FDA and Health Canada approvals create durable competitive advantage: regulatory clearance supports hospital adoption, reimbursement pathways and clinical trust. This entrenched status reduces commercialization barriers for current and next‑gen devices over multiple years.
Emperor TAH Technical ProgressSuccessful first in vivo implants materially de‑risk the Emperor program, demonstrating feasibility beyond benchtop tests. That progress strengthens the company’s development pipeline, shortening the path to clinical trials and potential market expansion for a fully implantable TAH.
Strategic Engineering PartnershipPartnering with Hydrix brings critical systems engineering and regulated device experience, bolstering internal capabilities. This external expertise can accelerate product development, improve execution reliability and lower long‑term technical and regulatory risk for the Emperor program.
Bears Say
Persistent Cash BurnSustained large negative operating cash flow indicates the business requires ongoing external funding to sustain operations and development. This structural cash burn elevates refinancing, dilution and execution risk until the company achieves positive operating cash generation or secures durable, non‑dilutive funding.
Deep Unprofitability And Negative MarginsNegative gross margins and extreme net losses signal underlying unit economics challenges or insufficient scale. Without sustained gross margin improvement or major cost reductions, the company faces limited ability to generate operating leverage, constraining long‑term profitability prospects.
Capital Structure Strain & Financing EncumbrancesPrior high debt and new senior secured notes with first‑priority liens and warrant overlays create structural constraints: IP encumbrance, covenants and dilution risk can limit strategic flexibility, increase refinancing complexity and pressure future equity holders over multiple funding cycles.
Picard Medical, Inc. News
PMI FAQ
What was Picard Medical, Inc.’s price range in the past 12 months?
Picard Medical, Inc. lowest stock price was $1.01 and its highest was $13.68 in the past 12 months.
What is Picard Medical, Inc.’s market cap?
Currently, no data Available
When is Picard Medical, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Picard Medical, Inc.’s earnings last quarter?
Picard Medical, Inc. released its earnings results on Sep 15, 2025. The company reported -$0.102 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.102.
Is Picard Medical, Inc. overvalued?
According to Wall Street analysts Picard Medical, Inc.’s price is currently Overvalued.
Does Picard Medical, Inc. pay dividends?
Picard Medical, Inc. does not currently pay dividends.
What is Picard Medical, Inc.’s EPS estimate?
Picard Medical, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Picard Medical, Inc. have?
Picard Medical, Inc. has 73,701,180 shares outstanding.
What happened to Picard Medical, Inc.’s price movement after its last earnings report?
Picard Medical, Inc. reported an EPS of -$0.102 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 10.656%.
Which hedge fund is a major shareholder of Picard Medical, Inc.?
Currently, no hedge funds are holding shares in PMI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Picard Medical, Inc.
Picard Medical, Inc., through its subsidiaries, engages in the designing, manufacturing, production, supply, marketing, and sale of medical device products. The company offers SynCardia TAH, an artificial heart for patients that is designed to function as a failed human heart in patients suffering from advanced heart failure. The company operates in the USA, Europe, and internationally. The company was incorporated in 2021 and is based in Tucson, Arizona. Picard Medical, Inc. operates as a subsidiary of Hunniwell Picard I, Llc
Technical Analysis
Aethlon Medical
―
Venus Concept
―
Catheter Precision
―
Heart Test Laboratories, Inc.
―
Autonomix Medical, Inc.
―
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
0.17% Other Institutional Investors
99.77% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---